Irradiation enhances susceptibility of tumor cells to the antitumor effects of TNF-α activated adipose derived mesenchymal stem cells in breast cancer model

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mohammadpour, Hemn ^a,b   Pourfathollah, Ali Akbar ^a   Nikougoftar Zarif, Mahin ^c   Shahbazfar, Amir Ali ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Seoul National University   (South Korea)

^c HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^d UNIVERSITY OF TABRIZ   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DKK3 PROTEIN, MOUSE; SIGNAL PEPTIDE; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; MULTIMODALITY CANCER THERAPY; PROCEDURES; RADIOTHERAPY; TUMOR CELL LINE; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; RADIOTHERAPY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84976316481     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28433     Document Type: Article

References (48)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer. J. Clin. 65, 5-29 (2015).
2. Jagsi, R. Progress and controversies: radiation therapy for invasive breast cancer. CA Cancer. J. Clin. 64, 135-152 (2014).
3. Whelan, T. J. et al. Long-Term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362, 513-520 (2010).
4. Group, E. B. C. T. C. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-Analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 378, 1707-1716 (2011).
5. Bibault, J.-E. et al. Personalized radiation therapy and biomarker-driven treatment strategies: A systematic review. Cancer. Metastasis. Rev. 32, 479-492 (2013).
6. Klopp, A. H. et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer. Res. 67, 11687-11695 (2007).
7. Bianco, P. et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nature. Med. 19, 35-42 (2013).
8. Shah, K. Mesenchymal stem cells engineered for cancer therapy. Adv. Drug. Deliv. Rev. 64, 739-748 (2012).
9. Shi, Y. et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell. Res. 20, 510-518 (2010).
10. Sasportas, L. S. et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. 106, 106, 4822-4827 (2009).
11. Lee, R. H., Yoon, N., Reneau, J. C. & Prockop, D. J. Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell. stem. cell. 11, 825-835 (2012).
12. Refaat, A., Abd Rabou, A. & Reda, A. TRAIL combinations: The new trailfor cancer therapy (Review). Oncol. Lett. 7, 1327-1332 (2014).
13. Lathrop, M. et al. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer. Gene. Ther. 22, 44-54 (2015).
14. Veeck, J. & Dahl, E. Targeting the Wnt pathway in cancer: The emerging role of Dickkopf-3. Biochim. Biophys. Acta. 1825, 18-28 (2012).
15. Kim, S. M. et al. Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor Related Apoptosis Inducing Ligand Secreting Human Umbilical Cord Blood Derived Mesenchymal Stem Cells in Glioma Therapy. Stem. Cell 28, 2217-2228 (2010).
16. Mohammadpour, H., Pourfathollah, A. A., Zarif, M. N. & Tahoori, M. T. TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int. Immunopharmacol. 28, 1009-1017 (2015).
17. Ku, S. et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. haematologica. 95, 651-659 (2010).
18. Li, W. et al. Mesenchymal stem cells: A double-edged sword in regulating immune responses. Cell. Death. Differ. 19, 1505-1513 (2012).
19. Wong, R. S. Mesenchymal stem cells: Angels or demons? Biomed. Res. Int. 2011 (2011).
20. Leng, L. et al. Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. Biomaterials. 35, 5162-5170 (2014).
21. Zhao, Q. et al. MSCs derived from iPSCs with a modified protocol are tumor-Tropic but have much less potential to promote tumors than bone marrow MSCs. Proc. Natl. Acad. Sci. 112, 530-535 (2015).
22. Nakamura, K. et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene. Ther. 11, 1155-1164 (2004).
23. Hong, X., Miller, C., Savant-Bhonsale, S. & Kalkanis, S. N. Antitumor treatment using interleukin 12 secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64, 1139-1147 (2009).
24. Kim, N. et al. IL-21-Expressing Mesenchymal Stem Cells Prevent Lethal B-Cell Lymphoma Through Efficient Delivery of IL-21, Which Redirects the Immune System to Target the Tumor. Stem. Cells. Dev. 24, 2808-2821 (2015).
25. Kim, S. M. et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer. Res. 68, 9614-9623 (2008).
26. Abarzua, F. et al. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer. Res. 65, 9617-9622 (2005).
27. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 449, 557-563 (2007).
28. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer. 9, 239-252 (2009).
29. Tang, X.-J. et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer. Res. 34, 729-734 (2014).
30. Buchsbaum, D. J. et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer. Res. 9, 3731-3741 (2003).
31. Almasan, A. & Ashkenazi, A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine. Growth. Factor. Rev. 14, 337-348 (2003).
32. Chen, G. Y. & Nuz, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826-837 (2010).
33. Veeck, J. et al. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast. Cancer. Res. 10, 1-11 (2008).
34. Mohammadpour, H., Pourfathollah, A. A., Zarif, M. N. & Khalili, S. Key role of Dkk3 protein in inhibition of cancer cell proliferation: An in silico identification. J. Theor. Biol. 393, 98-104 (2016).
35. Takata, A. et al. Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells. Int. J. Gynecol. Cancer. 25, 372-379 (2015).
36. Chartier, C. et al. Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types. Cancer. Res, 0561.2015 (2015).
37. Troiani, T. et al. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin. Cancer. Res. 19, 6751-6765 (2013).
38. Mohammadpour, H. & Majidzadeh-A. K. Antitumor effect of conditioned media derived from murine MSCs and 5-Aminolevulinic acid (5-ALA) mediated photodynamic therapy in breast cancer in vitro. Photodiagnosis. Photodyn. Ther. 12, 238-243 (2015).
39. Lee, J.-K. et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLos One 8, e84256 (2013).
40. Seo, S. et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene. Ther. 18, 488-495 (2011).
41. Lee, R. H. et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell. stem. cell. 5, 54-63 (2009).
42. Balyasnikova, I. V. et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol. Ther. 22, 140-148 (2013).
43. Jeong, K. Y. et al. Irradiation induced localization of IL 12 expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int. J. Cancer. 137, 721-730 (2015).
44. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
45. Huang, B. et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer. Res. 66, 1123-1131 (2006).
46. English, K., Barry, F. P., Field-Corbett, C. P. & Mahon, B. P. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology. lett. 110, 91-100 (2007).
47. Mohammadpour, H., Pourfathollah, A. A., Nikougoftar Zarif, M. & Hashemi, S. M. Increasing proliferation of murine adipose tissue-derived mesenchymal stem cells by TNF-α plus IFN-γ . Immunopharmacol. Immunotoxicol. 38, 68-76 (2016).
48. Fischer, A. H., Jacobson, K. A., Rose, J. & Zeller, R. Hematoxylin and eosin staining of tissue and cell sections. Cold. Spring. Harbor. Protocols 2008, pdb. prot4986 (2008).